↓ Skip to main content

Cytomegalovirus infection in transplant recipients

Overview of attention for article published in Clinics, July 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 544)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

24 news outlets
1 blog
5 tweeters
1 patent
1 Facebook page


108 Dimensions

Readers on

261 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Cytomegalovirus infection in transplant recipients
Published in
Clinics, July 2015
DOI 10.6061/clinics/2015(07)09
Pubmed ID

LS Azevedo, LC Pierrotti, E Abdala, SF Costa, TM Strabelli, SV Campos, JF Ramos, AZ Latif, N Litvinov, NZ Maluf, HH Caiaffa Filho, CS Pannuti, MH Lopes, VA Santos, CC Linardi, MA Yasuda, HH Marques


Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 261 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Brazil 1 <1%
Unknown 259 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 46 18%
Student > Bachelor 37 14%
Researcher 32 12%
Student > Ph. D. Student 27 10%
Other 22 8%
Other 50 19%
Unknown 47 18%
Readers by discipline Count As %
Medicine and Dentistry 98 38%
Biochemistry, Genetics and Molecular Biology 30 11%
Immunology and Microbiology 22 8%
Agricultural and Biological Sciences 19 7%
Pharmacology, Toxicology and Pharmaceutical Science 16 6%
Other 24 9%
Unknown 52 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 180. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2021.
All research outputs
of 18,823,067 outputs
Outputs from Clinics
of 544 outputs
Outputs of similar age
of 275,780 outputs
Outputs of similar age from Clinics
of 1 outputs
Altmetric has tracked 18,823,067 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 544 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,780 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them